Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...

AMPLIFY-7P randomized 144 post-resection, radiographically NED mKRAS PDAC patients and missed the prespecified DFS primary endpoint in the intent-to-treat analysis. Landmark assessments showed ~14% ...

FDA approved Skinvive by Juvéderm to reduce neck lines and improve neck appearance in adults over the age of 21. The approval marks the first and only hyaluronic acid injectable ...

Polaryx’s chief medical officer discusses the regulatory environment for rare, pediatric treatments and how it’s directly impacting clinical trials. Pharmaceutical Executive previously covered FDA’s ...

Partnering and investment efforts focus on executing registrational studies, leveraging patented formulation, differentiated mechanism, and an estimated five million eligible US patients to support ...

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues the field must evolve beyond the scale, ...

Price transparency remains limited due to heterogeneous baselines, missing “before” metrics, and variable sourcing models, ...

In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for ...

Pharmaceutical Executive: How can prohibitive costs for treatments be addressed? Lisa Bollinger: These are oftentimes very ...

Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...